XBiotech Inc. (NASDAQ:XBIT) Sees Large Decrease in Short Interest

XBiotech Inc. (NASDAQ:XBIT) was the target of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 800,100 shares, a decrease of 23.1% from the February 28th total of 1,040,000 shares. Approximately 4.1% of the company’s shares are short sold. Based on an average daily trading volume, of 63,700 shares, the short-interest ratio is currently 12.6 days.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of XBiotech by 2.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,770 shares of the biopharmaceutical company’s stock valued at $1,962,000 after acquiring an additional 5,500 shares during the last quarter. State Street Corp increased its holdings in XBiotech by 10.7% in the 3rd quarter. State Street Corp now owns 224,595 shares of the biopharmaceutical company’s stock valued at $1,736,000 after purchasing an additional 21,752 shares during the last quarter. Barclays PLC increased its holdings in XBiotech by 247.4% in the 3rd quarter. Barclays PLC now owns 26,343 shares of the biopharmaceutical company’s stock valued at $204,000 after purchasing an additional 18,761 shares during the last quarter. Geode Capital Management LLC raised its position in XBiotech by 5.1% in the third quarter. Geode Capital Management LLC now owns 452,264 shares of the biopharmaceutical company’s stock valued at $3,496,000 after purchasing an additional 22,059 shares during the period. Finally, Jane Street Group LLC acquired a new position in XBiotech during the third quarter worth $86,000. Institutional investors and hedge funds own 55.70% of the company’s stock.

XBiotech Price Performance

Shares of NASDAQ XBIT opened at $3.02 on Wednesday. XBiotech has a 1 year low of $2.94 and a 1 year high of $9.96. The company has a market capitalization of $92.07 million, a P/E ratio of -2.80 and a beta of 1.25. The company has a 50 day simple moving average of $3.30 and a 200-day simple moving average of $5.29.

XBiotech (NASDAQ:XBIT) last posted its earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.